News & Events
NSW GOVERNMENT ANNOUNCES PROOF OF CONCEPT GRANTS FOR LIFE
10 / 11 / 2008
Minister for State Development and Acting Minister for Small Business Ian Macdonald today announced nearly $1 million in grants to help innovative life science companies develop and commercialise new research projects. Mr Macdonald said 10 grants have been…
Nicholas Callinan appointed Chairman
30 / 10 / 2008
At the conclusion of the Company's annual general meeting today, Nicholas Callinan was appointed Chairman of Sunshine Heart, Inc. following the retirement of Malcolm McComas who remains as a non-executive director. Mr Callinan is the founder and managing partner of Collins…
2008 Annual General Meeting Chairman's Address
30 / 10 / 2008
Last month, Sunshine Heart achieved the most significant milestone in the short history of the Company. In September, the US Food and Drug Administration (FDA) granted conditional approval to undertake a 20 person US feasibility trial for the C-PulseTM heart assist device. …
Uptake Medical Presents Data from Safety & Feasibility Clinical Trial for Patients with Heterogeneous Emphysema at 2008 CHEST Meeting in Philadelphia
26 / 10 / 2008
Uptake Medical Corp., a developer of medical technologies for the minimally-invasive treatment of lung diseases including emphysema, announced today that it will present data from their first safety & feasibility clinical trial at the 2008 CHEST meeting in Philadelphia. The trial,…
Phenomix and Forest Laboratories to Collaborate on Development and Commercialization of Dutogliptin in Diabetes
23 / 10 / 2008
Forest Laboratories, Inc. (NYSE: FRX) and Phenomix Corporation today announced that they have entered into a definitive collaboration agreement to develop and commercialize dutogliptin (PHX1149) in North America. Dutogliptin is Phenomix' proprietary orally administered, small molecule…
FDA Approves Reimbursement Category for C-Pulse
25 / 09 / 2008
Sunshine Heart (ASX: SHC) announces that the US Food and Drug Administration (FDA) has approved Reimbursement Category B for the C-PulseT US clinical trial. C-Pulse is a heart assist therapy for patients suffering from moderate heart failure. This approval will provide…
Xenome initiates Phase II clinical trial of Xen2174 in acute pain
25 / 09 / 2008
Xenome Limited ("Xenome") announced today that it has initiated its latest clinical trial of Xen2174, a new drug for the treatment of moderate to severe pain. The phase II study is the first trial of Xen2174 for the control of acute postoperative pain and will enrol approximately 200…
Change of Chairman
24 / 09 / 2008
Sunshine Heart (ASX: SHC) announces the retirement of Malcolm McComas as Chairman at the conclusion of the Annual General Meeting on 30 October, 2008 and the appointment of Nicholas Callinan as new Chairman. Malcolm McComas to retire The Company's chairman Malcolm…
KaloBios Raises $20 Million in Series D Venture Financing
23 / 09 / 2008
KaloBios Pharmaceuticals, Inc. today announced that the company has raised $20 million in the first closing of its Series D venture financing. The financing was co-led by Mitsubishi UFJ Capital and Genzyme Ventures, both new investors, with the participation of the company's previous…
FDAOKs IDE for trial of C-Pulse in moderate heart failure patients
18 / 09 / 2008
By LYNN YOFFEE Medical Device Daily Staff Writer Patients with heart failure who no longer get symptom relief from medications may have a new treatment option on the horizon with the FDA's conditional approval this week of an investigational device exemption (IDE) to…
ChemGenex Completes $A12.9 Million Capital Raising Announces Share Purchase Plan for existing Australian resident shareholders
17 / 09 / 2008
ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today the successful completion of a $A12.9 million capital raising through a share placement to institutional and sophisticated investors (15,216,153 shares at $0.85 per share). In addition to the placement, ChemGenex is…
FDA Approval for C-Pulse US Clinical Trial
12 / 09 / 2008
Sunshine Heart (ASX: SHC) announces that it has received conditional approval from the US Food and Drug Administration (FDA) to begin its first US clinical trial for C-PulseT, a heart assist therapy for patients suffering from moderate heart failure. With FDA conditional…
Spinifex Secures A$12m Investment to Develop Pain Drug
04 / 09 / 2008
Investment by GBS Venture Partners, Brandon Capital and Uniseed First A$6m Tranche Received, Second at Phase II Phase II Trial Targeted for 2009 Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured venture…
Spinifex Pharmaceuticals
03 / 09 / 2008
Spinifex says it has investment of $12 million from GBS Venture Partners, Brandon Capital Partners and Uniseed to development pain management drug EMA401. Spinifex said the funding was in two tranches, with the first $6 million received and the second tranche targeted for…
Peplin Announces Executive Management Appointments
18 / 08 / 2008
Peplin, Inc. (ASX:PLI) announced today that Tom Wiggans has been appointed Chief Executive Officer effective immediately. Mr Wiggans is currently Chairman of Peplin's board of directors and will also continue in that role. Prior to joining Peplin, Tom Wiggans served as…
Peplin secures approximately US$24m in additional financing
18 / 08 / 2008
Peplin, Inc. (ASX:PLI) today announced the successful arrangement of a private placement of common stock and warrants to raise approximately US$24.0 million (Placement). The financing will primarily fund Phase III of clinical development of PEP005 (ingenol mebutate) for actinic (solar)…
Additional information lodged with FDA for US clinical trial
13 / 08 / 2008
Sunshine Heart, Inc. (ASX: SHC) has today lodged additional information with the US Food and Drug Administration (FDA) in support of the Company's Investigational Device Exemption (IDE) application for approval to undertake a US clinical trial of Sunshine Heart's innovative C-PulseTM heart…
Sales contracts worth $2.3 million signed since 1 July 2008
12 / 08 / 2008
Highlights: $1.2 million contract signed for Phase III schizophrenia study In total, nine sales contracts signed since 1 July 2008, worth $2.3 million $3 million in revenue already locked in for FY 2009 CogState Ltd (ASX:CGS) today announced…
Australian company Xenome presents Xen2174 data on relief of pain in cancer patients at international conference
01 / 08 / 2008
A new drug for the treatment of severe pain under development by Australian biotechnology company Xenome Limited ("Xenome") has shown promise for the relief of chronic pain in cancer patients in a Phase II clinical trial. Relief of pain in cancer patients continues to…
KaloBios Initiates Phase 1/2 Trial of HumaneeredT Monoclonal Antibody KB001 for Treatment of Pseudomonas Infections in Mechanically Ventilated Patients
19 / 05 / 2008
KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced the initiation of a Phase 1/2 clinical trial of KB001, a HumaneeredT, high-affinity antibody fragment that KaloBios is developing for the treatment of Pseudomonas aeruginosa infections. …
Uptake Medical Announces Successful Completion of Patient Enrollment in Pilot Safety & Feasibility Clinical Trial for Patients with Heterogeneous Emphysema
16 / 05 / 2008
Uptake Medical announced today that it has completed patient enrolment in a phase I safety and feasibility clinical trial for the company's proprietary minimally invasive Bronchoscopic Thermal Vapor AblationT (BTVAT) treatment for patients suffering from heterogeneous emphysema with upper…
Novasys Medical Secures $49.5 Million in Series D Financing to Expand Commercialization of its Renessar Treatment for Incontinence in Women
15 / 05 / 2008
Novasys Medical, Inc., a developer of innovative therapies in women's health, announced today that it has secured $49.5 million in Series D preferred stock financing. The round was led by Versant Ventures, with ThreeArch Partners and Skyline Ventures also participating as new investors. The…
Underwritten rights issue to raise $5.4 million
05 / 05 / 2008
Sunshine Heart, Inc. (ASX: SHC) today announced the terms of an underwritten non-renounceable rights issue to raise $5.4 million. Under the rights issue, eligible shareholders will be invited to subscribe for 4 new shares for every 11 shares held at the record date at an offer price of 7…
KaloBios Expands Senior Management Team -- Adds Project Management and Additional Business Development Expertise --
05 / 05 / 2008
KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced two additions to its senior management team that significantly strengthen the company's project management and pharmaceutical business development expertise. Jeanne Y. Jew, previously Vice…
KaloBios Completes Patient Dosing in its U.S. Phase 1 Trial of Its Third Drug Candidate, KB003 -- First HumaneeredT Anti-GM-CSF Monoclonal Antibody Part of Comprehensive Inflammation Development Program --
28 / 04 / 2008
KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced that the company has completed dosing subjects in a U.S. Phase 1 clinical trial of its third drug candidate, KB003. The study is a placebo-controlled, single-dose, dose-escalation Phase 1 trial in…